Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

CGRP Antibodies as Prophylaxis in Migraine

Edvinsson, Lars LU (2018) In Cell 175(7). p.1719-1719
Abstract

Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF. Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system.... (More)

Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF. Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
in
Cell
volume
175
issue
7
pages
1 pages
publisher
Cell Press
external identifiers
  • scopus:85058023044
ISSN
0092-8674
DOI
10.1016/j.cell.2018.11.049
language
English
LU publication?
no
id
a749175e-a6b7-43e7-b2b4-99f6780916e2
date added to LUP
2018-12-18 13:10:31
date last changed
2022-04-25 19:56:26
@misc{a749175e-a6b7-43e7-b2b4-99f6780916e2,
  abstract     = {{<p>Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF. Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.</p>}},
  author       = {{Edvinsson, Lars}},
  issn         = {{0092-8674}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{1719--1719}},
  publisher    = {{Cell Press}},
  series       = {{Cell}},
  title        = {{CGRP Antibodies as Prophylaxis in Migraine}},
  url          = {{http://dx.doi.org/10.1016/j.cell.2018.11.049}},
  doi          = {{10.1016/j.cell.2018.11.049}},
  volume       = {{175}},
  year         = {{2018}},
}